Marathon Petroleum stock pivots toward Gulf Coast after refinery sale
Natera stock lifts outlook as oncology testing accelerates
Nasdaq stock faces two CFO investor conferences next week
National Bank of Canada stock expands reach with Embark deal
Ecolab stock posts Q3 growth, margin gains and 2027 target
NextEra Energy stock faces 4.83 billion US dollar merger test
Lam Research stock: 15 million US dollars for STEM partnership
Siemens Balances Record Cash Generation Against a Cautious Analyst Call
Volkswagen's Road From Emden to 2027 Runs Through a Recall and a Rethink in Wolfsburg
Cheniere Energy stock: Q3 strength lifts 2026 outlook
Nucor stock: DCF model points to modest cash-flow upside
Microsoft stock faces power-cost test as AI build expands
Micron Technology stock gets AI boost from US$1 billion Anthropic bet
KLA Corporation stock gets stronger outlook after Q1 revenue beat
Nike stock: Performance business offers a bright spot before Investor Day
General Dynamics stock builds on record backlog and higher outlook
Fastenal stock tracks broader October industrial demand
KKR stock enters UK offshore wind JV after GBP 12 billion close
Eli Lilly stock lower after China approves orforglipron pill
Intuitive Surgical stock adds Humana executive to its board
McKesson stock lifts fiscal 2027 outlook after strong Q2
Nebius Stock: Prepayments Now Underwrite the Build, but the Clock Is Running
Delta Air Lines stock faces lawsuit over windowless window seats
BYD Puts Product Pipeline to the Test as Tang Pre-Sales Open and Tai 9 Date Set
Bargain Hunters Step In After Gold's October Low, but the Fed Still Holds the Cards
Almonty's Q3: A C$50 Million Bottom Line, a C$47.9 Million Paper Boost, and a Canadian Court Date
Northrop Grumman stock joins Hermeus on high-Mach aircraft
Coca-Cola FEMSA stock faces cash-flow test after 182.7% gain
GE Vernova stock tests hydrogen capability in two turbine platforms
JPMorgan Chase stock faces AI credit test as loans reach $29 billion
IBM stock sets quantum roadmap for 1,040 qubits in 2027
Johnson & Johnson stock advances as prostate drug combo enters Phase 3